HC Wainwright Cuts Earnings Estimates for Vigil Neuroscience

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Research analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Vigil Neuroscience in a report issued on Tuesday, May 27th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.84) for the year, down from their previous forecast of ($0.64). HC Wainwright currently has a “Neutral” rating and a $8.00 target price on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share. HC Wainwright also issued estimates for Vigil Neuroscience’s FY2027 earnings at ($0.15) EPS, FY2028 earnings at $0.26 EPS and FY2029 earnings at $0.63 EPS.

Vigil Neuroscience (NASDAQ:VIGL) last announced its earnings results on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04.

VIGL has been the subject of a number of other research reports. Guggenheim set a $8.00 price objective on shares of Vigil Neuroscience and gave the company a “neutral” rating in a report on Thursday, May 22nd. JMP Securities reissued a “market perform” rating on shares of Vigil Neuroscience in a research report on Thursday, May 22nd. Citizens Jmp lowered Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 22nd. Mizuho cut Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 23rd. Finally, Stifel Nicolaus cut Vigil Neuroscience from a “buy” rating to a “hold” rating and lowered their target price for the stock from $11.00 to $8.00 in a research note on Wednesday. Ten investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.80.

Vigil Neuroscience Price Performance

Shares of NASDAQ:VIGL opened at $7.88 on Thursday. The firm has a market capitalization of $367.78 million, a PE ratio of -3.83 and a beta of 1.90. Vigil Neuroscience has a 1 year low of $1.31 and a 1 year high of $7.95. The firm’s 50-day moving average is $2.79 and its two-hundred day moving average is $2.45.

Institutional Investors Weigh In On Vigil Neuroscience

A number of large investors have recently modified their holdings of VIGL. BVF Inc. IL lifted its position in shares of Vigil Neuroscience by 121.3% during the 1st quarter. BVF Inc. IL now owns 4,013,633 shares of the company’s stock worth $7,144,000 after purchasing an additional 2,200,000 shares during the last quarter. 683 Capital Management LLC raised its stake in Vigil Neuroscience by 24.3% in the first quarter. 683 Capital Management LLC now owns 1,740,000 shares of the company’s stock valued at $3,097,000 after buying an additional 340,000 shares in the last quarter. Aberdeen Group plc lifted its holdings in Vigil Neuroscience by 226.3% during the 1st quarter. Aberdeen Group plc now owns 1,724,520 shares of the company’s stock worth $3,070,000 after buying an additional 1,196,048 shares during the last quarter. Blair William & Co. IL lifted its holdings in Vigil Neuroscience by 219.1% during the 1st quarter. Blair William & Co. IL now owns 1,033,577 shares of the company’s stock worth $1,840,000 after buying an additional 709,677 shares during the last quarter. Finally, Woodline Partners LP boosted its position in shares of Vigil Neuroscience by 239.1% during the 4th quarter. Woodline Partners LP now owns 488,756 shares of the company’s stock worth $831,000 after acquiring an additional 344,614 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.